GPCM
MDNA

Granite Point Capital Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Granite Point Capital Management’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-325,000
Closed -$270K – 123
2022
Q3 		$270K Buy
+325,000
New +$367K 0.11% 82

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Granite Point Capital Management's MDNA Position: Q4 2022 in Review

Granite Point Capital Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2022, closing a stake of 325,000 shares — an estimated $270K sold.

Granite Point Capital Management first reported a position in MDNA in Q3 2022 and held it in 1 quarter. The position peaked at $270K in Q3 2022. 27 funds tracked by Wall St. Rank hold MDNA as of Q4 2022.

  • Granite Point Capital Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2022 after selling out during the quarter.
  • Granite Point Capital Management sold 325,000 Medicenna Therapeutics Corp. Common Shares shares in Q4 2022, an estimated $270K.
  • Granite Point Capital Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2022 and held it in 1 quarter.
  • Granite Point Capital Management's Medicenna Therapeutics Corp. Common Shares position peaked at $270K in Q3 2022.
  • 27 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2022.

Based on Granite Point Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.